Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3359609

Drug Profile

GSK 3359609

Alternative Names: GSK-609; GSK3359609

Latest Information Update: 27 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Merck Sharp & Dohme
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Head and neck cancer
  • Phase II Non-small cell lung cancer
  • Phase I/II Multiple myeloma; Solid tumours

Most Recent Events

  • 21 Nov 2019 Phase-II/III clinical trials in Head and neck cancer (Combination therapy, Recurrent, Metastatic disease, First-line therapy) in Canada, Australia (IV) (NCT04128696)
  • 22 Oct 2019 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Sweden, Spain, Netherlands, Canada, Australia (IV) (NCT04126200) (EudraCT2019-001138-32)
  • 10 Oct 2019 GSK 3359609 is still in phase-I trials for Solid tumours (Monotherapy) in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top